This document has been translated from the Japanese original for reference
purposes only. In the event of any discrepancy between this translated
document and the Japanese original, the original shall prevail. Sosei Group
Corporation makes no warranty of any nature as to the accuracy of thisEnglish translation and assumes no responsibility for this translation or for
direct, indirect or any other form of damages arising from the translation.

Matters for Online Disclosure under the Law and
Articles of Incorporation

Notes to the Consolidated Financial
Statements
Notes to the Non-Consolidated
Financial Statements
27th Term (April 1, 2016 – March 31, 2017)

Sosei Group Corporation
The Notes to the Consolidated Financial Statements and Notes to
the Non-Consolidated Financial Statements are provided toshareholders through inclusion on the Company’s Internet website(http://www.sosei.com/) in accordance with the law and theprovisions of Article 14 of the Articles of Incorporation.

Notes to the Consolidated Financial Statements
1.

Notes on significant matters that serve as the basis for preparation of the consolidated
financial statements(1) Standards for preparation of the consolidated financial statements
The consolidated financial statements have been prepared in conformance with International
Financial Reporting Standards (hereinafter “IFRS”) based on Paragraph 1, Article 120 of the
Corporate Accounting Rules. Some statements and notes required by IFRS have been omitted
pursuant to the provisions of the latter part of the Paragraph.
(2) Matters related to the scope of consolidation
1) Consolidated subsidiaries
i. Number of subsidiaries: 7
ii. Names of principal consolidated subsidiaries
Sosei Co., Ltd.
Sosei R&D Ltd.
Activus Pharma Co., Ltd.
Heptares Therapeutics Ltd.
iii. Changes in the scope of consolidation
JITSUBO Co., Ltd., which was a consolidated subsidiary in the previous fiscal year, isremoved from the scope of consolidation from the fiscal year under review since theCompany’s ownership ratio decreased due to the third-party allocation of shares.
(3) Matters related to application of the equity method
1) Non-consolidated subsidiaries and affiliates accounted for by the equity method
i. Number of non-consolidated subsidiaries and affiliates accounted for by the equity method:
1ii. Names of principal companies
JITSUBO Co., Ltd.
iii. Changes in the scope of application of the equity method
JITSUBO Co., Ltd., which was a consolidated subsidiary in the previous fiscal year, is includedin affiliates accounted for by the equity method from the fiscal year under review since theCompany’s ownership ratio decreased due to the third party allocation of shares.
(4) Matters related to the fiscal year, etc. of consolidated subsidiaries
The settlement date of Sosei RMF1 Limited Partnership for Investment is December 31. Upon
preparing the consolidated financial statements, financial statements based on the provisional
settlement of accounts as of the consolidated settlement date are used. The settlement dateof other consolidated subsidiaries coincides with the end of consolidated fiscal year.
(5) Matters related to accounting policies
1) Valuation standards and methods for significant assets
i. Valuation standards and methods for financial assets
・ Derivatives
Derivatives are initially recognized at fair value on the date the contract is concluded andrecalculated at fair value after initial recognition.

・ Non-derivatives
Recognition and measurement of financial instruments“Trade and other receivables” are recognized on the date of occurrence and otherfinancial assets are recognized on the transaction date on which the Company
becomes a contractual party of the financial instrument, and are initially measured atfair value plus transactions costs.
Financial liabilities are recognized on the date on which the Company becomes acontractual party of the financial instrument, and are measured at fair value net oftransaction costs.
Derecognition of financial instruments
When contractual rights on cash flow from financial instruments expire, or whencontractual rights to receive cash flow from financial instruments are transferred by theGroup through a transaction in which all risk and economic value attending ownershipof the financial instrument are effectively transferred, recognition of financial
instruments is cancelled.
Recognition of financial instruments is cancelled when contractual obligations are
exempted or cancelled or when they expire.
The Group categorizes financial instruments as follows.
Available-for-sale financial assets: Non-derivate financial assets designated asavailable-for-sale financial assets or which are not categorized in any of the categories
below. These assets are initially measured at face value at the time of recognition andthen re-measured at fair value at the end of each fiscal period. Changes in fair value
are recognized as other comprehensive income. When asset recognition is cancelled,
the cumulative total recognized in equity as other comprehensive income is reclassified
into financial income or financial expenses.
Receivables: Non-derivative financial assets in which the payment amount is fixedor can be fixed and which do not have a public value on an active market. These assets
are initially measured at fair value at the time of recognition, and measured withdepreciation using the effective interest method at the end of each fiscal period after
deducting impairment loss. “Trade and other receivables” is in this category.
Financial liabilities measured with depreciation: Non-derivative financial obligations.
These liabilities are initially measured at fair value at the time of recognition, and aremeasured with depreciation using the effective interest method at the end of each fiscal
period. “Trade and other payables” and “Interest-bearing liabilities” are in this category.
Financial liabilities measured with fair value through net profit or loss: Contingent
consideration and appraisal value of repayment obligations to the limited partners of a
subsidiary, RMF1 Limited Partnership for Investment (hereinafter “RMF1”). Theseliabilities are initially measured at fair value at the time of recognition and realized or
unrealized profit or loss arising from the changes in fair value is recognized as net profit
or loss at the time it is generated. “Conditional prices for business combinations” and“Other financial liabilities” are in this category.
・Impairment loss on financial assets
Regarding financial assets measured with depreciation, evaluations are conducted
on whether objective evidence exists showing that impairment has occurred at each

reporting date. Regarding financial assets, assets are judged as impaired when
objective evidence shows that impairment has occurred after initial recognition of theasset and when that impairment loss can be rationally predicted to negatively impact
estimated future cash flow of the financial asset.
Objective evidence showing that financial assets measured with depreciation are
impaired includes non-performance of payment or default by an obligor, extension of
the collection deadline on receivables conducted under terms that would not likely beapplied if the situation had not occurred, signs of bankruptcy of the obligor or issuing
company, the disappearance of an active market, etc.
The Group considers evidence of impairment of financial assets measured withdepreciation for each individual asset and overall. Regarding significant individual
financial assets, impairment is assessed individually. Regarding significant individual
financial assets for which separate impairment is not necessary, whether impairment
has occurred but has not yet been reported is assessed on an overall basis. Individual
financial assets that are not significant are grouped on the basis of similarity of risk
characteristics and impairment is assessed overall.
When assessing impairment on an overall basis, Group management judges thepossibility that the actual loss is too high or too low based on past trends anddepending on current economic and credit conditions, after considering past trends
related to default potential, recovery timing and amount of loss occurring, and makes
adjustments.
Regarding impairment loss on financial assets measured with depreciation, it ismeasured as the difference between the book value and the current value of estimatedfuture cash flow net of the asset’s initial effective interest, and recognized in net
income/loss through the allowance for doubtful accounts. The allowance for doubtful
accounts related to financial assets measured with depreciation is directly impaired
when future recovery cannot be realistically expected and all collateral is realized ortransferred to the Group.
When an event where impairment loss is reduced after impairment loss has beenrecognized occurs, the decrease in impairment loss (decrease to the allowance for
doubtful accounts) is reversed in net income/loss. Regarding impairment loss, it isreversed up to an amount not exceeding depreciation at the time impairment loss wasreversed in the case impairment loss was not recognized.
ii. Valuation standards and methods for non-financial assets
・Property, plant and equipment
Property, plant and equipment is measured using the cost model at the acquisition cost
net of cumulative depreciation and cumulative impairment. The acquisition cost includes
costs directly related to acquiring the asset and the initial estimate of costs for dismantling
and removal and restoration of the installation location to its original state.
・Goodwill and intangible assets
Goodwill
Goodwill that occurs when a subsidiary is acquired is stated in “Goodwill” using theacquisition cost net of cumulative impairment. Regarding measurement of goodwill at thetime of initial recognition, it is measured using the fair value of transfer considerations,
including the amount recognized for non-controlling interests, net of the net recognizedvalue (normally, the fair value) of identifiable assets and assumed liabilities at the time of
the acquisition.
Goodwill is not amortized; it is allocated to cash-generating units identified based on
the region where business is conducted and type of business, and an impairment test is
conducted each term, or each time there are signs of impairment.
Intangible assets
Intangible assets are measured using the cost model; individually acquired intangible
assets with estimated service lives that can be defined are measured at the acquisition
cost net of cumulative amortization and cumulative impairment. The acquisition cost
includes costs directly related to acquiring the asset.
Development assets
Outlays for research activities are recognized as costs in the period they occurred.
Internally generated intangible assets that occur at the development stage arerecognized only when all of the following can be substantiated.
・ Technical feasibility of completing an intangible asset that can be used or sold・ Intention to complete the intangible asset and then use it or sell it
・ Ability to use or sell the intangible asset
・ Method by which the intangible asset will create future economic benefit with strong
potential
・ Possibility of using financial or other resources that will be necessary to complete
the intangible asset and use it or sell it
・ Ability to reliably measure outlays caused by the intangible asset during its period
of development
The amount initially recognized for internally generated intangible assets is the total ofcosts that occurred from the date that the intangible asset initially met the above
recognition standards. When an internally generated intangible asset cannot berecognized, development outlays are expensed in the period they occur.
Internally generated intangible assets after initial recognition are stated, just as withother intangible assets, at the acquisition cost net of cumulative amortization andcumulative impairment.
Intangible assets acquired through business combinations and recognized separatelyfrom goodwill are stated at the acquisition cost net of cumulative amortization andcumulative impairment after the initial recognition at fair value as of the acquisition datein a policy similar to that applicable to intangible assets acquired independently.
Impairment of non-financial assets
Regarding the book values of the Group’s non-financial assets, the existence of any
signs of impairment is judged on each reporting date. If signs of impairment exist, theasset’s recoverable value is estimated. For goodwill and intangible assets withindeterminate service lives or that cannot yet be used, the recoverable value is estimatedin a given period in each consolidated fiscal year.
The recoverable value of assets or cash-generating units is the value in use or fairvalue net of disposition costs, whichever is higher. In the calculation of value in use,

estimated future cash flow is discounted to present value using a pre-tax discount ratethat reflects the time value of money and risks inherent to the asset. Regarding cashgenerating units, assets groups are the smallest unit generating cash flow that is basicallyindependent from the cash inflows of other assets or asset groups as a result of continued
use.
Regarding cash-generating units for goodwill, goodwill is determined based on units
managed for the purposes of internal reporting, but, in principle, each company is a cashgenerating unit.
Corporate assets do not generate independent cash inflow, so when there are signs of
impairment in corporate assets, the recoverable value of the cash-generating unit towhich the corporate asset belongs is calculated and the determination made.
Impairment loss is recognized in net income/loss when the book value of the asset or
cash-generating unit exceeds the recoverable value. Impairment loss recognized inconnection with cash-generating units is first allocated so that the book value of goodwill
allocated to that cash-generating unit decreases, and is next allocated so that the bookvalues of other assets within the cash-generating unit decrease proportionally.
Regarding impairment loss related to goodwill, reversal is not conducted. Regarding
impairment loss on other assets recognized in the past, the existence of signs showingthat the loss has decreased or been eliminated is determined on each reporting date. If
there are signs of impairment reversal and the estimate used for determining recoverable
value has changed, impairment loss is reversed.
Impairment loss is reversed up to an amount not exceeding the book value after
deducting necessary depreciation or amortization costs from it in the case impairment
loss was not recognized.
2) Depreciation methods for significant depreciable assets
i. Property, plant and equipment
Depreciation is calculated by calculating depreciable value using the straight-line method
over the estimated service life of each component.
Estimated service lives used in calculating depreciation are as follows.
Buildings and structures: 3-15 years
Machinery and equipment: 5-8 years
Tools, furniture and fixtures: 3-10 years
When asset depreciation methods, estimated service lives and residual values arereviewed at the end of each fiscal year and there are changes, they are applied toward thefuture as changes in accounting estimates.
ii. Intangible assets
For amortization, the amortizable amount is calculated using the straight-line method overthe estimated service lives of constitutive elements. Asset amortization methods, estimatedservice lives and residual values are reviewed at the end of each fiscal year, and when therechanges, they are applied toward the future as changes in accounting estimates.
The main estimated service lives used in calculating amortization are as follows.
Base technology: 20 years

Customer-related assets: 20 years
Intangible assets with indefinite service lives and intangible assets that are not yet usable
are not amortized; impairment tests are conducted during a certain period each year andwhen there are signs of impairment.
iii. Leases (Lessee)
Leases in which nearly all the risk and reward of ownership are transferred to the Groupare categorized as finance leases. Finance leases are stated as assets at the fair value ofthe lease property calculated when the lease began or the present value of minimum lease
payments, whichever is lower, and depreciated over the lease period or service life,
whichever is shorter. Lease obligations are recognized as interest-bearing liabilities. The
portion of lease payments corresponding to finance charges is recognized as an expense
over the lease period using the effective interest method.
Lease agreements other than finance leases are categorized as operating leases.
Operating lease payments are recognized as expenses on a straight-line basis over thelease period.
3) Accounting standards for significant income and expenses
The Group calculates income based on the fair value of having been received or
receivable income.
i. Sales of goods
Income from sales of goods is recognized when the significant risks and rewards ofownership of the goods are transferred to the customer, there is no ongoing managerial
commitment to the goods, an inflow of economic benefit related to the transaction isprobable, and cost and income amounts occurring related to the transaction can be reliability
measured.
The timing of the transfer of risks and rewards of goods ownership differs depending on
the individual sales contract, but normally income is recognized when the goods aretransferred to the customer or on the shipping date, etc.
ii. Royalty revenue, milestone revenue and lump-sum payments
Royalty revenue that is income received as a fixed rate of sales after the product ismarketed, is stated in accordance with the terms of license agreements.
Lump-sum payments that is income received when licensing agreements are concluded
and milestone income that is income received based on the progress of research anddevelopment (when a development stage is reached that has been stipulated in advance inthe agreement) are received from third parties. Such income is normally stated withachievement of the milestone agreed to by both parties.
4) Standards for conversion of significant foreign-denominated assets and liabilities toJapanese currency
i. Foreign-denominated transactions
Foreign-denominated transactions are converted to the functional currencies of Group
companies at prevailing exchange rates on the transaction date. Foreign-denominatedmonetary assets and liabilities on the term-end date are reconverted to the functional

currency at the exchange rate on the term-end date. Foreign-denominated monetary assets
and liabilities measured at fair value are reconverted to the functional currency at theexchange rate on the date fair value is calculated. Non-monetary items measured based on
acquisition cost are calculated using the exchange rate on the transaction date.
Exchange differences resulting from reconversion or settlement are recognized in net
income/loss for that period.
ii. Financial statements of foreign operations
The assets and liabilities of foreign operations (overseas subsidiaries, etc.) are converted
to Japanese yen at the exchange rate on the term-end date, and their income and expenses
are converted to Japanese yen at the average exchange rate.
Foreign exchange differences resulting from conversion of the financial statements offoreign operations are recognized in “Other comprehensive income”, and the cumulative
difference is stated in “Other components of equity” on the consolidated statement offinancial position.
5) Business combinations
Business combinations are accounted for using the acquisition method. Acquisition
considerations are measured as the total of assets transferred and liabilities assumed in
exchange for control of the acquired business and the fair value on the transaction date ofequity instruments issued by the Company. If the acquisition value exceeds the fair value ofidentifiable assets and liabilities, it is stated as goodwill on the consolidated statement
financial position. Conversely, if less, it is directly stated as income in the consolidated
statement of comprehensive income. If initial accounting for a business combination is notcompleted by the end of the term in which the business combination occurred, accounting
is conducted with provisional amounts, and the provisional amounts are revised in themeasurement period within one year of the acquisition date. Acquisition costs that occurred
are accounted for as expenses.
2.

3.

Notes on consolidated statement of financial position(1) Cumulative depreciation on property, plant and equipment: 553 million yen
Notes on the consolidated statement of changes in equity(1) Matters related to total shares outstanding

Share class
CommonsharesShares at beginning of
consolidated fiscal year
16,855,284

Increase in shares duringconsolidated fiscal year

Decrease in shares duringconsolidated fiscal year

60,900－Shares at end of consolidated
fiscal year
16,916,184

Note: The increase in total shares outstanding is due to issuing 60,900 shares through theexercise of stock options.
(2) Matters related to subscription warrants, etc. at the end of the consolidated fiscal year underreview
Type and number of shares for subscription warrants at the end of the consolidated fiscal
year under review (excluding warrants prior to the first day of their exercise period):
Common shares 65,200

4.

Notes on financial instruments(1) Matters related to financial instruments
1) Policies for management of financial instruments
The Group limits its investments to short-term instruments with minimal risk and does notengage in speculative transactions. Also, funds are primarily procured by issuing new stockand borrowing from banks, etc.
2) Financial instrument content and their risks, and risk management framework
Trade and other receivables are exposed to customer credit risk. Regarding this risk,
deadlines and balances are managed for each transaction partner. Trade and otherpayables have payment deadlines of within one year.
The Group limits its investments to short-term deposits, etc. to reduce risk.
(2) Matters related to the fair value, etc. of financial instruments
Amounts stated on the consolidated statement of financial position, fair values and theirdifferences on March 31, 2017 are as follows.
Amount stated on
consolidated
statement offinancial position(JPY Million)*Type

Fair value(JPY Million)

Difference(JPY Million)

Cash and cash equivalents

13,89913,899－Trade and other receivables

1,382

1,382

－

Trade and other payables△1,547△1,547－

Interest-bearing liabilities△6,900△6,900－△5,230△5,230

－

△625

△625

－

Contingent
relatedconsideration
tocorporateacquisition
Other financial liabilities*Items stated as liabilities are marked as negative (△).
Notes: Matters related to calculation methods for the market values of financial instruments
1. Cash and cash equivalents, trade and other receivables, and trade and other payables
These are settled over short time periods, so market values are nearly equivalent to bookvalues and so accord with book values.
2. Interest-bearing liabilities
Borrowings are valued using the amortized cost method, and book values are reasonableapproximations of fair values.
3. Interest-bearing liabilities scheduled for repayment after the consolidated settlement dateWithin 1 year

(JPY Million)
Within 1-5years

Interest-bearing liabilities (including longterm)△1,990△4,910

4. Contingent consideration related to corporate acquisition
Such considerations are calculated by discounting by a fixed discount rate upon taking into
account conditions such as the probability of occurrence in future cash flow.
5. Other financial liabilities
Other financial liabilities are valued according to the fluctuation in the fair value of the assetof the Company’s subsidiary, RMF1.
5.

6.

Notes on per-share information(1) Equity attributable to owners of parent company per share(2) Basic net income per share¥1,704.94¥579.97

Notes on important subsequent events(1) Important share purchase
MiNA Holdings Limited(a) Summeay of business combination
The Company made investment for a 25.6% equity share of a private UKbiopharmaceutical company and pioneer in RNA activation therapeutics (small activating
RNAs, saRNAs) through Sosei R&D.
(b) Purpose of purchase
The agreement is consistent with the Company’s stated inorganic growth strategy, which is
focused on identifying innovative clinical-stage assets that have the potential to be developed
rapidly and in addition could be commercialized by the Company in select markets. This
inorganic strategy is complementary to the Company’s organic strategy, which is focused on
advancing a growing pipeline of novel pre-clinical and clinical drug candidates originatingfrom Heptares Therapeutics, a subsidiary of the Company.
(c) Summary of MiNA
Company name

MiNA Holdings Limited

Address

96 Kenshington High Street, London, W8 4SG, United
Kingdom

Representative’s nameRobert Habib, CEOand title
Business description

Pioneering novel treatments harnessing gene activation

Founded2008

mechanisms through small activating RNA (saRNA)(d) The date of share purchase
2 May, 2017

(e) Method of purchaseCash in compensation for the shares(f) Amount of purchase¥5,057 million
Note: A payment agreement on contingent consideration is included and necessary
adjustments to consideration for the acquisition may be carried out. At this point, we do not
identify the amount of assets and liabilities of MiNA that the Group will acquire.

This document has been translated from the Japanese original for reference
purposes only. In the event of any discrepancy between this translated
document and the Japanese original, the original shall prevail. Sosei Group
Corporation makes no warranty of any nature as to the accuracy of thisEnglish translation and assumes no responsibility for this translation or for
direct, indirect or any other form of damages arising from the translation.
Notes to the Non-Consolidated Financial Statements
1.

Notes on matters related to significant accounting policies(1)
1)

Asset valuation standards and methods
Marketable securities
A. Subsidiary stock: At cost determined by the moving-average method(2)
1)

Fixed asset depreciation methods
Property, plant and equipment: The declining balance method is used. However, the straight-line method is used forfacilities attached to buildings and structures acquired on or after April 1, 2016. The main service lives are as follows.
Buildings (facilities attached to buildings): 15 years
Tools, furniture and fixtures: 4-20 years

2)

Intangible fixed assets
The straight-line method is used.
For internal-use software, the straight-line method is used based on the estimated useful life (5 years) internally.

(3)

Accounting for deferred assets
Stock issuance expenses(4)
1)

Expensed in full at the time of payment.

Recognition standards for allowances
Allowance for doubtful accounts
To provide for credit loss on accounts receivable and other accounts, an estimated unrecoverable amount is set aside
based on historical credit loss rates for ordinary receivables and based on individual considerations for receivables
specified as doubtful, etc.

2)

Allowance for bonuses
To provide for the payment of employee bonuses, of the total estimated amount, the amount estimated to be incurred
as an expense that fiscal year is set aside.

(5)Standards for conversion of significant foreign-denominated assets and liabilities to Japanese currency
Foreign-denominated monetary claims and obligations are converted to Japanese yen based on spot exchange rates
on the term-end date, and translation differences are accounted for as income/loss.

(6)

Other matters that serve as the basis for preparation of the financial statements
Accounting for consumption taxes, etc.
Consumption taxes, etc. are accounted for using the tax-exclusion method.

2.

Notes on changes in accounting policies(Application of Practical Solution on a Change in Depreciation Method due to Tax Reform 2016)
In accordance with the amendment of the Corporation Tax Act, the Company applied “Practical Solution on a Change inDepreciation Method due to Tax Reform 2016” (Practical Issues Task Force (PITF) No. 32, June 17, 2016) from the fiscal year
under review and has changed the method of depreciation for facilities attached to buildings and structures acquired on or after
April 1, 2016 from the declining balance method to the straight line method.
The effect of this change on non-consolidated financial statements for the fiscal year under review is immaterial.

3.

Notes on changes in presentation method“Accounts receivable from affiliated companies,” which was included in “Other” current assets until the previous fiscal year(¥353 million in the previous fiscal year), is presented separately since it increased monetary importance.

4.

Notes on the balance sheet(JPY Million)(1) Cumulative depreciation on property, plant16

and equipment(2) Monetary claims and obligations to subsidiaries and affiliates (excluding
presented items)
Monetary obligations to subsidiaries and144

affiliates
5.

Notes on the income statement(JPY Million)

Transactions with subsidiaries and affiliates

6.

Operating transactions

1,499

Non-operating transactions

2,332

Notes on the statement of changes in shareholders’ equity
No treasury stock is held.

7.

Notes on tax effect accounting(1)

Main causes for the occurrence of deferred tax assets(JPY Million)

Deferred tax assets
Tax loss carryforward
Stock in subsidiaries and affiliates
Other

499
3,324
346

Deferred tax assets subtotal

4,169

Valuation allowance-4,169Total deferred tax assets-

8.

Notes on transactions with related parties(1)

Subsidiaries, etc.
EndingTransaction
Name of

Share of voting

Relationshipcompany,

rights holding

with relatedetc.

(held) (%)

parties

Transaction
TypebalanceamountAccount

content

(JPY

(JPY

million)Million)Long-term
accounts

Contracted forOperational535

12 receivable-

management
contracts

subsidiaries

operations
Sosei Co.,

DirectLtd.

holding

Subsidiary

and affiliates

100.0
Loans ofLong-term
545

Financialfundsloans tosupport

Recovery ofsubsidiaries

545
345
and affiliates

funds
Loans ofDirectSubsidiary

Long-term
840

Activus
Pharma Co.,

Financialfundsloans tosupport

Recovery ofsubsidiaries

940

100.0
holdingLtd.

590
and affiliates

funds

Accounts
Contracted for
Sosei R&D

100.0
Ltd.

receivable-

Operational

DirectSubsidiarysubsidiaries

contracts

holding44

166

management
operations

and affiliates
Accounts
Contracted forreceivable-

Operational

subsidiaries

contracts
operations

Heptaresand affiliates

DirectSubsidiary

1,373

1,313

management

100.0

Therapeutics
holding

Accounts

AdvanceLtd.
Reimbursementof

payable topayment of

66

5,146
cost

JITSUBO

DirectCo., Ltd.

holding

Affiliate

43.5

contingent

subsidiaries

consideration

and affiliates

Underwriting

Underwritingof capitalof capitalincreaseincrease

1,000

－

－

Notes:
1.

Transaction amounts do not include consumption taxes, etc.; term-end balances include consumption taxes, etc.

2.

Prices and other transaction terms are determined upon discussion and agreement by the two parties premised on terms
equivalent to other parties unrelated to the Company.

3.

Loans of funds to Sosei Co., Ltd. and Activus Pharma Co., Ltd. are determined upon considering market interest rates.
Collateral is not received.

4.

An allowance for doubtful accounts of ¥955 Million has been set aside for doubtful subsidiary accounts.

(2)

Officers and major individual shareholders, etc.
EndingTransaction

Share ofRelationshipTransaction

voting rights
Type

Account
content

holdingbalanceamountwith related

Name

(JPY

(JPY

million)Million)parties(held) (%)
Executive

Malcolm

Directly

Weir

held

Officer0

Officer andPayment

of

Executive

contingent

Viceconsideration

218

-

-

159

-

-

President
Executive

Fiona

Directly

Marshallheld

Officer0

Officer andPayment

of

Executive

contingent

Viceconsideration

President

Note:
1. The price and other transaction conditions are determined based on the contract contents similar to those used for third parties
unrelated to the Company.

9.

Notes on per-share information(1) Net assets per share¥2,414.01(2) Net income per share¥59.45